Scrip RSS Feedhttps://insights.citeline.comThe Latest News & Analysis from ScripWed, 23 Sep 2026 22:04:57 +0000en1hourly1 https://insights.citeline.com/scrip/business/strategy/novo-ceo-doustdar-insists-on-disciplined-dealmaking-DTRUDBIYUVCYRHSDBPICOXUSRI/<![CDATA[Novo CEO Doustdar Insists On Disciplined Dealmaking]]>premium

      
]]> https://feeds.feedblitz.com/~/969561506/0/scrip~Novo-CEO-Doustdar-Insists-On-Disciplined-Dealmaking/https://insights.citeline.com/scrip/business/strategy/novo-ceo-doustdar-insists-on-disciplined-dealmaking-DTRUDBIYUVCYRHSDBPICOXUSRI/
      
]]> Wed, 23 Sep 2026 12:14:10 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/fortunes-turn-for-roches-sefaxersen-as-igan-pivot-yields-phase-iii-win-CVYD6XQWGJCTRHM3EZZRAWDB5Y/<![CDATA[Fortunes Turn For Roche’s Sefaxersen As IgAN Pivot Yields Phase III Win ]]>premium

      
]]> https://feeds.feedblitz.com/~/969590630/0/scrip~Fortunes-Turn-For-Roche%e2%80%99s-Sefaxersen-As-IgAN-Pivot-Yields-Phase-III-Win/https://insights.citeline.com/scrip/r-and-d/clinical-trials/fortunes-turn-for-roches-sefaxersen-as-igan-pivot-yields-phase-iii-win-CVYD6XQWGJCTRHM3EZZRAWDB5Y/
      
]]> Wed, 23 Sep 2026 14:32:11 +0000 https://insights.citeline.com/scrip/business/deals/china-rd-will-continue-to-transform-biopharma-as-partner-and-rival-CWAN3OXI7JGOXMWBXNMH66NO3U/<![CDATA[China R&D Will Continue To Transform Biopharma – As Partner And Rival]]>premium

      
]]> https://feeds.feedblitz.com/~/969609410/0/scrip~China-RD-Will-Continue-To-Transform-Biopharma-%e2%80%93-As-Partner-And-Rival/https://insights.citeline.com/scrip/business/deals/china-rd-will-continue-to-transform-biopharma-as-partner-and-rival-CWAN3OXI7JGOXMWBXNMH66NO3U/
      
]]> Wed, 23 Sep 2026 16:40:04 +0000 https://insights.citeline.com/scrip/therapeutic-category/immunological/immunovant-fcrn-misses-in-cle-but-all-eyes-on-late-stage-studies-FQY3EPK6KRCERAQKOLD5653L24/<![CDATA[Immunovant FcRn Misses In CLE, But All Eyes On Late-Stage Studies ]]>premium

      
]]> https://feeds.feedblitz.com/~/969618662/0/scrip~Immunovant-FcRn-Misses-In-CLE-But-All-Eyes-On-LateStage-Studies/https://insights.citeline.com/scrip/therapeutic-category/immunological/immunovant-fcrn-misses-in-cle-but-all-eyes-on-late-stage-studies-FQY3EPK6KRCERAQKOLD5653L24/
      
]]> Wed, 23 Sep 2026 17:25:56 +0000 https://insights.citeline.com/scrip/business/financing/enveda-to-dig-deeper-as-it-mines-nature-for-drugs-using-ai-JWCY77X7T5E45JVIDTUCJLVB2Q/<![CDATA[Enveda To Dig Deeper As It Mines Nature For Drugs Using AI]]>premium

      
]]> https://feeds.feedblitz.com/~/969652658/0/scrip~Enveda-To-Dig-Deeper-As-It-Mines-Nature-For-Drugs-Using-AI/https://insights.citeline.com/scrip/business/financing/enveda-to-dig-deeper-as-it-mines-nature-for-drugs-using-ai-JWCY77X7T5E45JVIDTUCJLVB2Q/
      
]]> Wed, 23 Sep 2026 20:56:53 +0000 https://insights.citeline.com/scrip/focus-on-asia/india/biopharmas-factory-of-the-future-and-moving-out-of-the-dark-ages-UIZMZH35LBGXVPXHYR24XUJZ6U/<![CDATA[Biopharma’s Factory Of The Future And Moving Out Of The “Dark Ages” ]]>premium

      
]]> https://feeds.feedblitz.com/~/969538748/0/scrip~Biopharma%e2%80%99s-Factory-Of-The-Future-And-Moving-Out-Of-The-%e2%80%9cDark-Ages%e2%80%9d/https://insights.citeline.com/scrip/focus-on-asia/india/biopharmas-factory-of-the-future-and-moving-out-of-the-dark-ages-UIZMZH35LBGXVPXHYR24XUJZ6U/
      
]]> Wed, 23 Sep 2026 09:35:32 +0000 https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/obesity/roche-heralds-enicepatide-as-best-in-class-after-second-mid-stage-win-OBA2BX62PFBO5MURFYYDCOTLDA/<![CDATA[Roche Heralds Enicepatide As Best-In-Class After Second Mid-Stage Win]]>premium

      
]]> https://feeds.feedblitz.com/~/969494552/0/scrip~Roche-Heralds-Enicepatide-As-BestInClass-After-Second-MidStage-Win/https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/obesity/roche-heralds-enicepatide-as-best-in-class-after-second-mid-stage-win-OBA2BX62PFBO5MURFYYDCOTLDA/
      
]]> Tue, 22 Sep 2026 17:59:17 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/amgens-dazodalibep-outlook-is-brighter-after-first-phase-iii-readout-O6O3CEGVGBE3FKKFJBIC7OJFS4/<![CDATA[Amgen’s Dazodalibep Outlook Is Brighter After First Phase III Readout]]>premium

      
]]> https://feeds.feedblitz.com/~/969501890/0/scrip~Amgen%e2%80%99s-Dazodalibep-Outlook-Is-Brighter-After-First-Phase-III-Readout/https://insights.citeline.com/scrip/r-and-d/clinical-trials/amgens-dazodalibep-outlook-is-brighter-after-first-phase-iii-readout-O6O3CEGVGBE3FKKFJBIC7OJFS4/
      
]]> Tue, 22 Sep 2026 20:45:12 +0000 https://insights.citeline.com/scrip/therapeutic-category/immunological/celldex-hits-success-in-csu-phase-iii-setting-up-for-2027-bla-filing-FC5YTKHL7JDCXPOD7YYEN47CSM/<![CDATA[Celldex Hits Success In CSU Phase III, Setting Up For 2027 BLA Filing ]]>premium

      
]]> https://feeds.feedblitz.com/~/969501887/0/scrip~Celldex-Hits-Success-In-CSU-Phase-III-Setting-Up-For-BLA-Filing/https://insights.citeline.com/scrip/therapeutic-category/immunological/celldex-hits-success-in-csu-phase-iii-setting-up-for-2027-bla-filing-FC5YTKHL7JDCXPOD7YYEN47CSM/
      
]]> Tue, 22 Sep 2026 20:51:22 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/viking-delivers-on-weight-loss-maintenance-with-less-frequent-dosing-BZ2LYXIYWJE3ZA73AAUEO5LBDI/<![CDATA[Viking Delivers On Weight Loss Maintenance With Less-Frequent Dosing]]>premium

      
]]> https://feeds.feedblitz.com/~/969503759/0/scrip~Viking-Delivers-On-Weight-Loss-Maintenance-With-LessFrequent-Dosing/https://insights.citeline.com/scrip/r-and-d/clinical-trials/viking-delivers-on-weight-loss-maintenance-with-less-frequent-dosing-BZ2LYXIYWJE3ZA73AAUEO5LBDI/
      
]]> Tue, 22 Sep 2026 21:56:31 +0000 https://insights.citeline.com/scrip/business/stock-watch/stock-watch-a-quantum-of-biosimilar-solace-DVPZTL66OBFKHJKQ2RWSRDNQJ4/<![CDATA[Stock Watch: A Quantum Of Biosimilar Solace ]]>premium

      
]]> https://feeds.feedblitz.com/~/969490244/0/scrip~Stock-Watch-A-Quantum-Of-Biosimilar-Solace/https://insights.citeline.com/scrip/business/stock-watch/stock-watch-a-quantum-of-biosimilar-solace-DVPZTL66OBFKHJKQ2RWSRDNQJ4/
      
]]> Tue, 22 Sep 2026 16:09:46 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/otsukaioniss-ulefnersen-scores-in-als-but-only-in-a-rare-subtype-N4BUBVIIMJHHRINQCWXLDZL37M/<![CDATA[Otsuka/Ionis’s Ulefnersen Scores In ALS, But Only In A Rare Subtype]]>premium

      
]]> https://feeds.feedblitz.com/~/969502511/0/scrip~OtsukaIonis%e2%80%99s-Ulefnersen-Scores-In-ALS-But-Only-In-A-Rare-Subtype/https://insights.citeline.com/scrip/r-and-d/clinical-trials/otsukaioniss-ulefnersen-scores-in-als-but-only-in-a-rare-subtype-N4BUBVIIMJHHRINQCWXLDZL37M/
      
]]> Tue, 22 Sep 2026 21:15:41 +0000 https://insights.citeline.com/scrip/focus-on-asia/india/takeda-dr-reddys-secure-first-mover-window-for-qdenga-in-india-dengvaxia-out-E4I32ADZ3ZH7VHA4BOIQAHFQZY/<![CDATA[Takeda-Dr Reddy’s Secure First-Mover Window For Qdenga In India, Dengvaxia Out]]>premium

      
]]> https://feeds.feedblitz.com/~/969429674/0/scrip~TakedaDr-Reddy%e2%80%99s-Secure-FirstMover-Window-For-Qdenga-In-India-Dengvaxia-Out/https://insights.citeline.com/scrip/focus-on-asia/india/takeda-dr-reddys-secure-first-mover-window-for-qdenga-in-india-dengvaxia-out-E4I32ADZ3ZH7VHA4BOIQAHFQZY/
      
]]> Mon, 21 Sep 2026 14:52:05 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/jjs-multibillion-dollar-caplyta-ambitions-backed-by-new-data-in-bipolar-mania-G3ABH5C7KZBP5MXMDBCD2DSTTU/<![CDATA[J&J’s Multibillion-Dollar Caplyta Ambitions Backed By New Data In Bipolar Mania]]>premium

      
]]> https://feeds.feedblitz.com/~/969446279/0/scrip~JJ%e2%80%99s-MultibillionDollar-Caplyta-Ambitions-Backed-By-New-Data-In-Bipolar-Mania/https://insights.citeline.com/scrip/r-and-d/clinical-trials/jjs-multibillion-dollar-caplyta-ambitions-backed-by-new-data-in-bipolar-mania-G3ABH5C7KZBP5MXMDBCD2DSTTU/
      
]]> Mon, 21 Sep 2026 22:09:21 +0000 https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-telix-and-pharming-secure-fda-approvals-HXDRIYXHIZFSJOAQVM64SHV54I/<![CDATA[Pipeline Watch: Telix And Pharming Secure FDA Approvals]]>premium

      
]]> https://feeds.feedblitz.com/~/969418907/0/scrip~Pipeline-Watch-Telix-And-Pharming-Secure-FDA-Approvals/https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-telix-and-pharming-secure-fda-approvals-HXDRIYXHIZFSJOAQVM64SHV54I/
      
]]> Mon, 21 Sep 2026 13:05:59 +0000 https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/obesity/novo-looks-to-direct-to-consumer-and-diversification-to-lift-growth-6YXKHNIOQBF7PP4GYLF4V6HKO4/<![CDATA[Novo Looks To Direct-To-Consumer And Diversification To Lift Growth]]>premium

      
]]> https://feeds.feedblitz.com/~/969417935/0/scrip~Novo-Looks-To-DirectToConsumer-And-Diversification-To-Lift-Growth/https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/obesity/novo-looks-to-direct-to-consumer-and-diversification-to-lift-growth-6YXKHNIOQBF7PP4GYLF4V6HKO4/
      
]]> Mon, 21 Sep 2026 12:52:40 +0000 https://insights.citeline.com/scrip/business/deals/bayer-legacy-drug-clean-up-continues-with-stivarga-sale-I63EECQCCJCA7H3F5IBM6WM4ZM/<![CDATA[Bayer Legacy Drug Clean-Up Continues With Stivarga Sale ]]>premium

      
]]> https://feeds.feedblitz.com/~/969431111/0/scrip~Bayer-Legacy-Drug-CleanUp-Continues-With-Stivarga-Sale/https://insights.citeline.com/scrip/business/deals/bayer-legacy-drug-clean-up-continues-with-stivarga-sale-I63EECQCCJCA7H3F5IBM6WM4ZM/
      
]]> Mon, 21 Sep 2026 15:20:24 +0000 https://insights.citeline.com/scrip/business/deals/telixs-165bn-itm-deal-brings-isotope-supply-and-therapeutics-under-one-roof-6B4KABVY7JGSRAQHTJUSQHU2DE/<![CDATA[Telix’s $1.65bn ITM Deal Brings Isotope Supply And Therapeutics Under One Roof]]>premium

      
]]> https://feeds.feedblitz.com/~/969431108/0/scrip~Telix%e2%80%99s-bn-ITM-Deal-Brings-Isotope-Supply-And-Therapeutics-Under-One-Roof/https://insights.citeline.com/scrip/business/deals/telixs-165bn-itm-deal-brings-isotope-supply-and-therapeutics-under-one-roof-6B4KABVY7JGSRAQHTJUSQHU2DE/
      
]]> Mon, 21 Sep 2026 15:28:24 +0000 https://insights.citeline.com/scrip/therapeutic-category/immunological/cues-csu-data-lands-in-the-pocket-showing-benefit-over-xolair-AND5EI6T5JE2LFWT4BRNDA4Y54/<![CDATA[Cue’s CSU Data Lands In The Pocket, Showing Benefit Over Xolair ]]>premium

      
]]> https://feeds.feedblitz.com/~/969439448/0/scrip~Cue%e2%80%99s-CSU-Data-Lands-In-The-Pocket-Showing-Benefit-Over-Xolair/https://insights.citeline.com/scrip/therapeutic-category/immunological/cues-csu-data-lands-in-the-pocket-showing-benefit-over-xolair-AND5EI6T5JE2LFWT4BRNDA4Y54/
      
]]> Mon, 21 Sep 2026 18:47:04 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/beacon-ready-to-approach-regulators-with-gene-therapy-for-xlrp-RJZA734IJ5DOXNN6XWXRCGYHAA/<![CDATA[Beacon Ready To Approach Regulators With Gene Therapy For XLRP]]>premium

      
]]> https://feeds.feedblitz.com/~/969445142/0/scrip~Beacon-Ready-To-Approach-Regulators-With-Gene-Therapy-For-XLRP/https://insights.citeline.com/scrip/r-and-d/clinical-trials/beacon-ready-to-approach-regulators-with-gene-therapy-for-xlrp-RJZA734IJ5DOXNN6XWXRCGYHAA/
      
]]> Mon, 21 Sep 2026 21:25:05 +0000 https://insights.citeline.com/scrip/partnered-content/the-shift-toward-precision-immunology-in-rheumatology-trials-WT543RLFHJG2VM3MWFZSJ6XP4U/<![CDATA[The Shift Toward Precision Immunology in Rheumatology Trials]]>free

      
]]> https://feeds.feedblitz.com/~/969417938/0/scrip~The-Shift-Toward-Precision-Immunology-in-Rheumatology-Trials/https://insights.citeline.com/scrip/partnered-content/the-shift-toward-precision-immunology-in-rheumatology-trials-WT543RLFHJG2VM3MWFZSJ6XP4U/
      
]]> Mon, 21 Sep 2026 12:47:57 +0000 https://insights.citeline.com/scrip/focus-on-asia/china/six-chinese-drugs-on-course-for-blockbuster-status-as-five-year-plan-sets-the-bar-KEBII2JIZNC7RIE2KMLCA2O4D4/<![CDATA[Six Chinese Drugs On Course For Blockbuster Status As Five-Year Plan Sets The Bar]]>premium

      
]]> https://feeds.feedblitz.com/~/969409928/0/scrip~Six-Chinese-Drugs-On-Course-For-Blockbuster-Status-As-FiveYear-Plan-Sets-The-Bar/https://insights.citeline.com/scrip/focus-on-asia/china/six-chinese-drugs-on-course-for-blockbuster-status-as-five-year-plan-sets-the-bar-KEBII2JIZNC7RIE2KMLCA2O4D4/
      
]]> Mon, 21 Sep 2026 09:25:31 +0000